Mazda Canada Inc. Announces Leadership Transition Français
RICHMOND HILL, ON, June 20, 2025 /CNW/ - Today, Mazda Canada Inc. announces that effective October 1, 2025, David Klan, President and CEO will retire and be succeeded by current Senior Director and Chief Operating Officer, Amy Fleming.
A 33-year veteran of Mazda, David has held numerous executive positions globally since he started in 1992, including Director of Marketing and Regional General Manager at Mazda North American Operations in the United States, and General Manager of Global Brand Marketing at Mazda Motor Corporation in Japan. After returning to Canada in 2009, David led the company's national sales, marketing, and regional operations as Senior Director before becoming President & CEO in 2019.
Under his six years of leadership as President and CEO of Mazda Canada, David has championed a strong people-first culture and led the company to record levels of business quality. Mazda Canada has also earned several prestigious accolades including a spot on the Greater Toronto's Top Employer List for ten consecutive years and earning the Canadian Automobile Dealers Association's top two awards - Highest Overall Satisfaction and Most Effective Dealer Communications – for six consecutive years.
"Every part of my journey at Mazda has been deeply rewarding, and it's been a pleasure working with the best teams in the business" said David Klan. "Mazda in Canada has outstanding momentum and it's a distinct privilege to hand over the reins to my chosen successor, Amy Fleming. Amy is an exceptional leader with unparalleled drive and dedication, and I'm confident she will continue to drive Mazda forward with vision and purpose."
Mazda Canada's incoming President and CEO, Amy Fleming, possesses a Bachelor of Business Administration from the Schwartz School of Business and Information Systems and is a graduate of St. Francis Xavier University. She started her career in automotive more than three decades ago at a dealership in her hometown of Antigonish, Nova Scotia where she worked while pursuing her studies. After graduation, she continued her automotive career in Ontario, working in both the corporate and retail side for several years. After developing a strong foundation in dealership operations, she joined Mazda Canada in 2006 and has been a key member of the executive team for the past decade. With her extensive involvement in all areas of the business, she has had a major positive impact on Mazda Canada's operations, notably amid the difficult period of the COVID-19 pandemic. She assumed the position of Senior Director and Chief Operating Officer in 2023 and currently oversees national sales, marketing, fixed operations, and customer experience operations. In recognition of her transformative leadership and commitment to putting people first, just last month, Fleming received the prestigious honor of being named one of the 100 Leading Women in the North American Automotive Industry by Automotive News for a second time. This marks the first time in Mazda Canada's history that a woman holds the role of President and CEO.
"It's an incredible honour to lead Mazda Canada at such a pivotal time in our industry," said Amy Fleming. "Under Dave's leadership, we've built a strong foundation for success, and I'm committed to continuing to build on that momentum with our talented team and passionate retailers across the country. With our award-winning product line-up, and our mission to building lasting emotional connections to our products and people, I'm excited for the future of Mazda in Canada."
"On behalf of Mazda Motor Corporation, I want to extend our appreciation to David for both his leadership and tremendous contributions over 33 years of service, and I am delighted to welcome Amy to her new role in Mazda Canada," said Jeff Guyton, Representative Director, Senior Managing Executive Officer and CFO, Mazda Motor Corporation. "Amy has twice been recognized as one of the Leading Women in the North American Auto Industry by Automotive News, and I am certain that Mazda Canada will continue its growth and success under Amy's leadership."
"On behalf of Mazda retailers across Canada, we extend our heartfelt thanks to Dave for his outstanding leadership and unwavering commitment to the Mazda brand," said Mitch Lewicki, Mazda Dealer Council Chair and General Manager of Park Mazda. "His vision and steady hand have guided Mazda Canada through a pivotal time, strengthening our position in a rapidly evolving market. As he moves into a well-earned retirement, we wish him all the best in this next chapter. We are also pleased to welcome Amy Fleming as the new President and CEO of Mazda Canada. Amy brings a deep understanding of both the retailer and OEM perspectives, and we are confident in her ability to build on our momentum. Her collaborative approach and strategic insight position Mazda Canada for continued success in the years ahead."
Klan will remain President and CEO until September 30, 2025, ensuring a smooth transition as Fleming, his close collaborator and the second consecutive Canadian in the role, assumes leadership.
About Mazda Canada Inc.
Proudly founded in Hiroshima, Japan, Mazda has a history of sophisticated craftsmanship and innovation, and a purpose to enrich life-in-motion for those it serves. By putting humans at the center of everything it does, Mazda aspires to create uplifting experiences with our vehicles and for people.
Mazda Canada Inc. is responsible for the sales and marketing, customer service and parts support of Mazda vehicles in Canada. Headquartered in Richmond Hill, Ontario, Mazda Canada has a nationwide network of 163 retail stores. For additional information visit Mazda Canada's media website at www.media.mazda.ca.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
21 minutes ago
- Cision Canada
Updated HR Research Links Effective Employee Onboarding to Engagement, Retention, and Culture: McLean & Company Resource
Global HR research and advisory firm McLean & Company has released an updated resource, Develop a Comprehensive Onboarding Program, that contains research insights and expert advice that will help HR leaders build engaging, high-impact onboarding experiences that extend beyond orientation. The firm's recently refreshed blueprint delivers step-by-step guidance to help organizations acclimate, guide, and develop new hires for improved retention, productivity, and long-term success. TORONTO, June 20, 2025 /CNW/ - First impressions matter, yet despite rising turnover and a greater emphasis on employee experience, many organizations still treat onboarding as a quick orientation, missing the opportunity to engage, equip, and retain new talent. McLean & Company's recently refreshed research, Develop a Comprehensive Onboarding Program, reframes onboarding as a months-long journey that directly shapes how quickly employees contribute, how connected they feel to the wider team, and how likely they are to stay. "Onboarding doesn't begin on day one – it begins the moment a candidate accepts the offer," says Kelly Berte, practice lead, HR Research & Advisory Services. "When treated as a strategic, shared responsibility between HR and leaders, onboarding becomes more than a process; it becomes a powerful driver of culture, clarity, and commitment." Despite its impact on engagement and turnover, the global research and advisory firm's insights highlight that onboarding remains one of the most misunderstood phases of the employee lifecycle. Too often, organizations delegate the process solely to HR, overlook manager involvement, or fail to adapt to hybrid realities. The result is disconnected new hires, extended ramp-up times, and preventable attrition. McLean & Company's research shows that effective onboarding programs should: Improve time to productivity by clarifying expectations and role success. Strengthen employee retention by fostering belonging and connection. Reinforce culture and employer brand through intentional socialization. The firm's Develop a Comprehensive Onboarding Program blueprint outlines a five-step process for HR to build a comprehensive onboarding program that aligns with business needs. The five steps are: Assess the current onboarding experience and define success metrics. Acclimate new hires by sharing essential organizational, administrative, and cultural information. Guide employees with performance clarity, goal-setting, and coaching from day one. Develop new hires with role-specific learning and long-term growth support. Implement and communicate the program for consistent and scalable adoption. Designed for evolving workplace realities, the updated blueprint provides guidance on navigating decentralized teams, leveraging onboarding technology, and tailoring the approach by region or role complexity. As organizations compete for talent and adapt to flexible work models, onboarding is becoming a critical component of the workplace. For new hires, McLean & Company advises that onboarding is often where their expectations are met with organizational reality, and that when done right, it sets the tone for long-term engagement and growth. "When onboarding is viewed as a shared responsibility between HR and leaders, it becomes a powerful driver of performance, and perhaps most importantly, trust," explains Berte. McLean & Company's blueprint includes customizable tools, diagnostics, and step-by-step resources to help HR teams assess current gaps and design onboarding programs that work, whether employees are in-office, hybrid, or fully remote. To support implementation, McLean & Company offers a dedicated workshop to help HR leaders apply the framework in their own organizational context. Learn more about the workshop here. Organizations looking to accelerate the development of their onboarding program may also benefit from McLean & Company's Develop a Comprehensive Onboarding Program workshop, or the firm's New Hire and Employee Exit Survey. For media inquiries or to connect with McLean & Company analysts for exclusive, research-backed insights on human resources, onboarding, culture, and employee experience, please contact Communications Manager Katie Tame at [email protected]. About McLean & Company McLean & Company pairs evidence-based research and immediately applicable tools with deep HR expertise to position organizations to meet today's needs and prepare for the future. The global HR research and advisory firm's member organizations enjoy comprehensive resources, full-service diagnostics, workshops, action plans, and advisory services for all levels of HR professionals, from executive leadership to HR leaders to HR team members, that help shape workplaces where everyone thrives. McLean & Company is a division of Info-Tech Research Group. Media professionals can register for unrestricted access to research across IT, HR, and software and hundreds of industry analysts through the firm's Media Insiders program. To gain access, contact [email protected]. SOURCE McLean & Company
Cision Canada
an hour ago
- Cision Canada
FÉRIQUE Fund Management expands its fund family with the launch of the FÉRIQUE 100% Equity Portfolio Français
MONTREAL, June 20, 2025 /CNW/ - FÉRIQUE Fund Management is pleased to announce the launch of the FÉRIQUE 100% Equity Portfolio, a new investment solution geared to long-term growth. This mutual fund will be available from June 26, 2025, to provide full exposure to global equity markets. The new fund responds to the growing demand for diversified investment solutions with full exposure to the equity markets. The FÉRIQUE 100% Equity Portfolio has a fund-of-funds structure, offering sound strategic diversification by region, sector and management style. "The portfolio has been designed and optimized to provide a simple and efficient gateway to the global equity markets," explained Francis Fortin, Vice President, Investments, at FÉRIQUE Fund Management. "It meets the needs of investors who want to take advantage of the return potential of the equity markets, while benefitting from rigorous management." The fund will be managed by FÉRIQUE Fund Management. In addition to offering regular rebalancing, the portfolio will have some of the industry's most competitive management expense ratios in its category. The new fund, which is available exclusively to engineering professionals, their families and their businesses, expands the investment options available to them, offering a solution geared to long-term growth. "Adding this fund enhances our offering so that we can better meet the varied profiles of investors who wish to invest in the FÉRIQUE Funds," Mr. Fortin added. "We're proud to continue developing solutions that support the financial independence of engineering professionals in Quebec." Founded in 1999, FÉRIQUE Fund Management ( is the manager of the FÉRIQUE Funds. It is the only not-for-profit mutual fund company in Canada dedicated solely to serving the interests of engineering professionals and their families. The company offers 18 mutual funds, including 6 portfolios representing the different asset classes required for healthy diversification. Fund management is entrusted to reputable external firms mandated by FÉRIQUE Fund Management according to their respective specialties. FÉRIQUE Funds total nearly $4.5 billion and has more than 24,000 participants as of March 31, 2025.
Cision Canada
2 hours ago
- Cision Canada
With Public Funding Under Pressure, Biotech Innovators Are Picking Up the Slack in Oncology
VANCOUVER, BC, June 20, 2025 /CNW/ -- USA News Group News Commentary – The costs of cancer drugs is skyrocketing, according to a recent report from Bloomberg. Analysts at Nova One Advisor estimate that the global oncology drugs market will grow at a 7.4% CAGR through to US$366.24 billion by 2034. Help doesn't appear to be coming from the public sector, as reports state that the current US administration could drastically reduce funding of the National Cancer Institute (NCI) by nearly 40%, the market is looking towards the private sector to pick up the slack and continue to make advancements in cancer treatment. For investors to note, plenty of oncology innovators have provided recent developments, including Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Immuneering Corporation (NASDAQ: IMRX), GRAIL, Inc. (NASDAQ: GRAL), Intensity Therapeutics, Inc. (NASDAQ: INTS), and Relay Therapeutics, Inc. (NASDAQ: RLAY). The global oncology market is expected to see strong growth over the next decade, with ResearchAndMarkets forecasting it to reach US$866.1 billion by 2034 at a 10.8% CAGR. A separate estimate from Vision Research Reports projects the market will surpass US$903.81 billion by the same year, growing at a 10.9% CAGR. Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) has entered a new phase of leadership with the appointment of Jared Kelly as Chief Executive Officer and member of the Board. Kelly brings a background in high-stakes biotech transactions and strategic immuno-oncology development, positioning him to guide the company through its next stage of clinical and business evolution. Before joining Oncolytics, Kelly served as General Counsel at Ambrx Biopharma, where he played a key role in its $2 billion acquisition by Johnson & Johnson. His earlier work includes advising life sciences firms on licensing, partnerships, and M&A while at Kirkland & Ellis LLP and Lowenstein Sandler LLP. Now leading Oncolytics, he steps into a company advancing pelareorep, a virus-based immunotherapeutic designed to work synergistically with checkpoint inhibitors and other agents across a range of solid and blood cancers. "Pelareorep's clinical data across multiple tumors is striking and represents the potential for a true backbone immunotherapy to address many in-need indications. Importantly, the data show that pelareorep creates a robust immunologic response in difficult tumors and increases survival in a patient population where survival has historically evaded most patients," said Jared Kelly, CEO of Oncolytics Biotech. "With a renewed focus and sharpened clinical development plan, we believe we will move pelareorep forward effectively and efficiently to a place where potential partners will see the value of a de-risked immunotherapy. I am excited to get to work accelerating development and unlocking significant value for stakeholders." Kelly's appointment signals a clear strategic focus: advancing pelareorep toward key late-stage milestones through a capital-conscious approach that remains open to strategic collaboration. Pelareorep currently holds FDA Fast Track designation for both metastatic pancreatic ductal adenocarcinoma (mPDAC) and HR+/HER2- metastatic breast cancer (mBC) —a rare dual recognition that underscores its regulatory momentum. Across multiple studies, the virus-based therapy has demonstrated consistent immune activation, broad combinability with checkpoint inhibitors and chemotherapies, and encouraging response rates in challenging cancer types. In mPDAC, pelareorep has achieved over 60% objective response rates in tumor-evaluable patients across Phase 1 and 2 trials—more than double what's typically seen in historical benchmarks. Separate analyses also reported two-year survival rates four to six times higher than control arms or prior studies. In HR+/HER2- mBC, two randomized Phase 2 trials (IND-213 and BRACELET-1) showed survival benefits supportive of further investigation. Meanwhile, a Phase 2 cohort in anal cancer pairing pelareorep with a checkpoint inhibitor reported partial or complete responses in nearly half of evaluable patients—substantially higher than historical norms for monotherapy in this setting. "Mr. Kelly's vision and track record is an extraordinary fit with the standout clinical data pelareorep has generated to date," said Wayne Pisano, Chair of the Board and outgoing Interim CEO of Oncolytics. "We believe Mr. Kelly's well-documented ability to prioritize clinical program development, execute successful financings, and attract the attention of large industry peers will help maximize Oncolytics' potential to deliver transformative outcomes for patients and exceptional value for investors." Kelly's compensation package includes equity grants and milestone-linked incentives tied to future financings and potential strategic transactions—aligning leadership priorities with long-term shareholder interests. The structure signals a commitment to advancing both clinical and corporate goals while preserving balance sheet discipline and maintaining appeal for potential partners. With multiple cohorts progressing in the GOBLET study—including those in pancreatic and anal cancer supported by external funding and regulatory engagement— Oncolytics is positioned to move forward with a combination of scientific momentum, financial agility, and renewed strategic focus. In other recent industry developments and happenings in the market include: Immuneering Corporation (NASDAQ: IMRX) reported positive Phase 2a data for atebimetinib (IMM-1-104) in combination with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer patients. At six months, the study showed 94% overall survival and 72% progression-free survival in 34 patients, with no median OS or PFS reached yet. "These exceptional data demonstrate the potential of atebimetinib plus mGnP to dramatically extend the lives of patients with advanced pancreatic cancer," said Ben Zeskind, Ph.D., Co-founder and CEO of Immuneering. "Our ultimate goal is to help cancer patients outlive their disease, and today's announcement represents an important milestone on that journey." The combination also demonstrated a 39% overall response rate, an 81% disease control rate, and a notably favorable tolerability profile. Many patients experienced deep, durable tumor regressions, including lesions rendered undetectable. The regimen was well tolerated, with an adverse event profile suggesting potential best-in-class positioning among MEK inhibitors. GRAIL, Inc. (NASDAQ: GRAL), recently announced strong top-line results from the PATHFINDER 2 registrational study evaluating its Galleri® multi-cancer early detection test in over 25,000 adults. "We are delighted to see very encouraging performance of the Galleri MCED test as a cancer screening tool in broad intended use populations of asymptomatic adults over 50 years of age in both the PATHFINDER 2 study and the NHS-Galleri trial's prevalent screening round," said Josh Ofman, MD, MSHS, President at GRAIL. "We would like to extend our sincere gratitude to all of the participants and investigators in both of these pivotal studies, who are collectively helping to realize the potential of this groundbreaking technology for population-scale multi-cancer early detection and move the field forward." The study showed a substantially higher positive predictive value (PPV) compared to the original PATHFINDER trial, with consistent specificity and cancer signal origin accuracy, and no serious safety concerns reported. GRAIL plans to submit these results to the FDA as part of its ongoing premarket approval process under Breakthrough Device Designation. Intensity Therapeutics, Inc. (NASDAQ: INTS) announced that the first patients in its ongoing Phase 2 INVINCIBLE-4 trial achieved high levels of tumor necrosis within eight days of receiving two doses of INT230-6, before starting standard-of-care immunochemotherapy for triple-negative breast cancer (TNBC). "We are excited to see that INT230-6 is achieving meaningful levels of necrosis in patients with evidence of immune activation," said Lewis H. Bender, President and CEO of Intensity. "TNBC patients risk their lives to achieve a pCR, and about forty percent fail to achieve the desired result." MRI scans showed substantial tumor destruction and inflammation, suggesting immune activation following direct intratumoral injection. The randomized study compares INT230-6 followed by standard treatment versus standard treatment alone, with pathological complete response (pCR) as the primary endpoint. Relay Therapeutics, Inc. (NASDAQ: RLAY) reported updated interim data from its Phase 1/2 study of RLY-2608 plus fulvestrant, showing a median progression-free survival (PFS) of 11.0 months in second-line patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer. "We are encouraged by the consistency of these updated RLY-2608 + fulvestrant data, which continue to show the potential benefit of a mutant-selective PI3Kα inhibitor for improving both the tolerability profile and progression free survival compared to standard of care," said Don Bergstrom, M.D., Ph.D., President of R&D at Relay Therapeutics. "We look forward to starting the first mutant-selective PI3Kα Phase 3 trial, ReDiscover-2, in the middle of this year." Among patients at the recommended Phase 3 dose, the clinical benefit rate reached 67%, and 39% had confirmed partial responses, with notably higher response rates in those with kinase mutations. The combination maintained a favorable tolerability profile, with low rates of high-grade adverse events and minimal treatment discontinuations. DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Oncolytics Biotech Inc.; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
